{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T19:41:09Z","timestamp":1784490069662,"version":"3.55.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100010793","name":"Pfizer Japan Inc","doi-asserted-by":"crossref","award":["WS2053019"],"award-info":[{"award-number":["WS2053019"]}],"id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There are limited data for direct comparisons of the efficacy of oral itraconazole (ITCZ) and oral voriconazole (VRCZ) therapy in the treatment of chronic pulmonary aspergillosis (CPA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective, follow-up, observational study of CPA patients enrolled in 2 previous multicenter trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 273 CPA patients, 59 and 101 patients started maintenance therapy with oral ITCZ and oral VRCZ, respectively, just after the end of acute intravenous therapy in each trial. At the end of the observation period in this follow-up study (median observation period, 731 days), the percentage of patients who showed improvement was lower in the ITCZ group than in the VRCZ group (18.2% vs 40.0%). However, after including stable patients, the percentages were 50.9% and 52.6%, respectively, in the ITCZ and VRCZ groups, which were not significantly different (P = .652). Multivariable Cox regression analysis showed no significant influence of the choice of initial maintenance treatment (ITCZ or VRCZ) on overall mortality as well as CPA-associated mortality. Multivariable logistic regression showed that oral ITCZ selection for initial maintenance therapy was an independent risk factor for hospital readmission and switching to other antifungal agents (odds ratio [OR], 3.1; 95% confidence interval [CI], 1.3\u20137.5 and OR, 5.7; 95% CI, 2.0\u201315.7, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Oral VRCZ for initial maintenance therapy showed better effectiveness than oral ITCZ for clinical improvement in CPA patients. There was no difference in crude mortality between initial maintenance therapy with VRCZ and ITCZ, especially in elderly CPA patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>UMIN000007055<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciz287","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T22:23:22Z","timestamp":1554330202000},"page":"835-842","source":"Crossref","is-referenced-by-count":19,"title":["Selection of Oral Antifungals for Initial Maintenance Therapy in Chronic Pulmonary Aspergillosis: A Longitudinal Analysis"],"prefix":"10.1093","volume":"70","author":[{"given":"Masato","family":"Tashiro","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences"},{"name":"Infection Control and Education Center, Nagasaki University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Takazono","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences"},{"name":"Department of Respiratory Medicine, Nagasaki University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Saijo","sequence":"additional","affiliation":[{"name":"Infection Control and Education Center, Nagasaki University Hospital"},{"name":"Department of Respiratory Medicine, Nagasaki University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Infection Control and Education Center, Nagasaki University Hospital"},{"name":"Department of Respiratory Medicine, Nagasaki University Hospital"},{"name":"Clinical Research Center, National Hospital Organization Nagasaki Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Imamura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital"},{"name":"Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiga","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences"},{"name":"Department of Respiratory Medicine, Nagasaki University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kakeya","sequence":"additional","affiliation":[{"name":"Department of Infection Control Science, Graduate School of Medicine, Osaka City University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunehiro","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Medical Center , Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Higashinagoya National Hospital , Nagoya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Kishi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issei","family":"Tokimatsu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Clinical Infectious Diseases, School of Medicine, Showa University , Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Higashinagoya National Hospital , Nagoya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Fujiuchi","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Asahikawa Medical Center , Hokkaido"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Yanagihara","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Nagasaki University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitsugu","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy and Mycoses, National Institute of Infectious Diseases , Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Ichihara","sequence":"additional","affiliation":[{"name":"Department of Laboratory Sciences, Yamaguchi University Graduate School of Medicine , Ube,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital"},{"name":"Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Kohno","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital"},{"name":"Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Izumikawa","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences"},{"name":"Infection Control and Education Center, Nagasaki University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"key":"2024111411410496200_CIT0001","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1183\/13993003.00583-2015","article-title":"Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management","volume":"47","author":"Denning","year":"2016","journal-title":"Eur Respir J"},{"key":"2024111411410496200_CIT0002","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000489474","article-title":"Treatment of chronic pulmonary aspergillosis: current standards and future perspectives","volume":"96","author":"Alastruey-Izquierdo","year":"2018","journal-title":"Respiration"},{"key":"2024111411410496200_CIT0003","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s12281-017-0304-7","article-title":"The management of chronic pulmonary aspergillosis: the UK National Aspergillosis Centre approach","volume":"11","author":"Maghrabi","year":"2017","journal-title":"Curr Fungal Infect Rep"},{"key":"2024111411410496200_CIT0004","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.3389\/fmicb.2018.01810","article-title":"Recent advances in diagnosing chronic pulmonary aspergillosis","volume":"9","author":"Takazono","year":"2018","journal-title":"Front Microbiol"},{"key":"2024111411410496200_CIT0005","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01062-2016","article-title":"Predictors of mortality in chronic pulmonary aspergillosis","author":"Lowes","year":"2017","journal-title":"Eur Respir J"},{"key":"2024111411410496200_CIT0006","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2169\/internalmedicine.52.9142","article-title":"Prognostic factors in 194 patients with chronic necrotizing pulmonary aspergillosis","volume":"52","author":"Nakamoto","year":"2013","journal-title":"Intern Med"},{"key":"2024111411410496200_CIT0007","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.rmed.2012.01.014","article-title":"Clinical characteristics and prognosis of chronic pulmonary aspergillosis","volume":"106","author":"Ohba","year":"2012","journal-title":"Respir Med"},{"key":"2024111411410496200_CIT0008","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/mmy\/myv093","article-title":"The risk factors for developing of chronic pulmonary aspergillosis in nontuberculous mycobacteria patients and clinical characteristics and outcomes in chronic pulmonary aspergillosis patients coinfected with nontuberculous mycobacteria","volume":"54","author":"Takeda","year":"2016","journal-title":"Med Mycol"},{"key":"2024111411410496200_CIT0009","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024111411410496200_CIT0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1749-6632.2012.06758.x","article-title":"Management of chronic pulmonary aspergillosis","volume":"1272","author":"Izumikawa","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"2024111411410496200_CIT0011","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/myc.12075","article-title":"Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature","volume":"56","author":"Agarwal","year":"2013","journal-title":"Mycoses"},{"key":"2024111411410496200_CIT0012","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1007\/s10096-012-1690-y","article-title":"Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial","volume":"31","author":"Cadranel","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024111411410496200_CIT0013","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1378\/chest.06-2441","article-title":"Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients","volume":"131","author":"Camuset","year":"2007","journal-title":"Chest"},{"key":"2024111411410496200_CIT0014","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.jinf.2005.08.022","article-title":"The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis","volume":"52","author":"Jain","year":"2006","journal-title":"J Infect"},{"key":"2024111411410496200_CIT0015","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s15010-012-0322-x","article-title":"Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan","volume":"40","author":"Saito","year":"2012","journal-title":"Infection"},{"key":"2024111411410496200_CIT0016","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s10156-012-0414-7","article-title":"Efficacy and safety of short- and long-term treatment of itraconazole on chronic necrotizing pulmonary aspergillosis in multicenter study","volume":"18","author":"Yoshida","year":"2012","journal-title":"J Infect Chemother"},{"key":"2024111411410496200_CIT0017","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jinf.2010.08.005","article-title":"Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan","volume":"61","author":"Kohno","year":"2010","journal-title":"J Infect"},{"key":"2024111411410496200_CIT0018","first-page":"167","article-title":"Intravenous liposomal amphotericin B versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan","volume":"61","author":"Kohno","year":"2018","journal-title":"Acta Medica Nagasakiensia"},{"key":"2024111411410496200_CIT0019","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1086\/376526","article-title":"Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review","volume":"37","author":"Denning","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2024111411410496200_CIT0020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/crj.12105","article-title":"Characteristics and outcomes of chronic pulmonary aspergillosis: a retrospective analysis of a tertiary hospital registry","volume":"9","author":"Camara","year":"2015","journal-title":"Clin Respir J"},{"key":"2024111411410496200_CIT0021","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jiac.2013.10.016","article-title":"Pathogenesis and clinical features of chronic pulmonary aspergillosis","volume":"20","author":"Izumikawa","year":"2014","journal-title":"J Infect Chemother"},{"key":"2024111411410496200_CIT0022","doi-asserted-by":"crossref","first-page":"e8315","DOI":"10.1097\/MD.0000000000008315","article-title":"Clinical features and diagnosis of chronic pulmonary aspergillosis in Chinese patients","volume":"96","author":"Hou","year":"2017","journal-title":"Medicine"},{"key":"2024111411410496200_CIT0023","first-page":"481","article-title":"Tuberculosis and its control","volume":"80","author":"Shimao","year":"2005","journal-title":"Kekkaku"},{"key":"2024111411410496200_CIT0024","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/cid\/cit411","article-title":"Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis","volume":"57","author":"Al-Shair","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2024111411410496200_CIT0025","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/jac\/dkm272","article-title":"Marked increase in steady-state serum levels achieved with itraconazole oral solution compared with capsule formulation","volume":"60","author":"Freeman","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2024111411410496200_CIT0026","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1439-0507.1999.00518.x","article-title":"Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules","volume":"42","author":"Glasmacher","year":"1999","journal-title":"Mycoses"},{"key":"2024111411410496200_CIT0027","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1128\/AAC.00514-12","article-title":"Correlation between triazole treatment history and susceptibility in clinically isolated Aspergillus fumigatus","volume":"56","author":"Tashiro","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411410496200_CIT0028","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1128\/AAC.05394-11","article-title":"Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan","volume":"56","author":"Tashiro","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411410496200_CIT0029","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1111\/ajt.14940","article-title":"Failure of voriconazole therapy due to acquired azole resistance in Aspergillus fumigatus in a kidney transplant recipient with chronic necrotizing aspergillosis","volume":"18","author":"Pilmis","year":"2018","journal-title":"Am J Transplant"},{"key":"2024111411410496200_CIT0030","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/cid\/civ885","article-title":"Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles?","volume":"62","author":"Verweij","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024111411410496200_CIT0031","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jiac.2016.12.004","article-title":"First clinical isolation report of azole-resistant Aspergillus fumigatus with TR34\/L98H-type mutation in Japan","volume":"23","author":"Toyotome","year":"2017","journal-title":"J Infect Chemother"},{"key":"2024111411410496200_CIT0032","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jiac.2016.01.015","article-title":"Multi-azole resistant Aspergillus fumigatus harboring Cyp51A TR46\/Y121F\/T289A isolated in Japan","volume":"22","author":"Hagiwara","year":"2016","journal-title":"J Infect Chemother"},{"key":"2024111411410496200_CIT0033","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jiac.2015.08.006","article-title":"Evaluation of clinical characteristics and prognosis of chronic pulmonary aspergillosis depending on the underlying lung diseases: emphysema vs prior tuberculosis","volume":"21","author":"Koyama","year":"2015","journal-title":"J Infect Chemother"},{"key":"2024111411410496200_CIT0034","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.resinv.2018.04.002","article-title":"Prognosis of chronic pulmonary aspergillosis in patients with pulmonary non-tuberculous mycobacterial disease","volume":"56","author":"Naito","year":"2018","journal-title":"Respir Investig"},{"key":"2024111411410496200_CIT0035","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/jac\/dkx390","article-title":"A CPAnet consensus statement on research priorities for chronic pulmonary aspergillosis: a neglected fungal infection that requires attention","volume":"73","author":"Godet","year":"2018","journal-title":"J Antimicrob Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz287\/28955221\/ciz287.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/70\/5\/835\/32449982\/ciz287.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/70\/5\/835\/32449982\/ciz287.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T12:27:51Z","timestamp":1731587271000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/70\/5\/835\/5432317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,8]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,4,8]]},"published-print":{"date-parts":[[2020,2,14]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz287","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3,1]]},"published":{"date-parts":[[2019,4,8]]}}}